Yesterday, we saw three blowouts and one nail-biter. The details are below, but if you’re caffeinated and must rush, here’s today’s ballot. I’m not particularly surprised that “IRA’s 10 selected

The first round is in the books, and we got one clear knockout, one big “upset,” and some clear trends on how you all thought about the environment in 2023.

Happy Boxing Day.  I know that “Boxing Day” has nothing to do with fighting, but it still seems like an apt day to launch Cost Curve Fight Club, an end-of-year

Cost Curve Fight Club starts on Tuesday as a way of making the break a little more entertaining for those of you who love this stuff too much to stay

Scheduling Note: Cost Curve isn’t exactly taking a holiday break. Instead, tomorrow, I’ll unveil the end-of-the-year “Cost Curve Fight Club” in which we can vote on (and, hopefully, argue about)

Scheduling Note: Cost Curve is off tomorrow, back Thursday. “Drug prices are not skyrocketing” is something that we say around here a lot. That doesn’t quite get at the truth,

So to strip things down to the basics, most cost-effectiveness analyses of drugs look at only three components: 1) What does it cost? 2) How does it extend or improve

Like what you’re reading? Forward to a friend. Received this as a forward? Sign up here. As a simple matter of data-dredging and analysis, this Public Citizen project -- covered

Scheduling Note: Cost Curve is off tomorrow. Back on Friday The two most important stories today are a pair out of Reuters on the obstacles that payers are erecting around

The House yesterday passed a mammoth health bill -- including some of the most sweeping PBM regulations ever -- by a huge margin. It includes a ban on spread pricing